View more job listings or post a job
PTC Therapeutics Director, Clinical Pharmacology
Alturas Analytics Quality Assurance Director
MCure Biosciences Scientist or Research Associate
Cytokinetics Director/Senior Director, DMPK
Inotiv Senior Toxicologist / Study Director
Vir Biotechnology Vice President, Molecular and Cellular Biology, to apply visit
Eurofins Discovery Marketing Assistant  
Vir Biotechnology Senior Scientist I, DMPK, to apply, click here,
Genentech Scientist, DMPK-Bioanalysis 
MilliporeSigma Chemistry Research Technology Specialists - Midwest 
Post a job


[Free Online Symposium] MAYZENT (Siponimod) for Multiple Sclerosis Treatment: The R&D Journey and Lessons Learned (a joint symposium by PBSS and CLSA)

Speakers: Shifeng Pan PhD (Executive Director, Discovery Chemistry; Novartis Institutes for Biomedical Research)
Organizers: Dewakar Sangaraju, Cyrus Khojasteh and Dennis Hu (all of Genentech)
Date: 2021-01-14
Time: 12:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2021-04-12  (it will close sooner if the seating cap is reached)

About the Topic

After 18 years of research and development, MAYZENT (siponimod) was approved by FDA in 2019 for the treatment of secondary progressive multiple sclerosis with active disease. Siponimod is the first therapy demonstrating statistically significant delay of disability progression in this patient population. In this presentation, we will share the R&D journey of MAYZENT.

This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry).

About the Speakers

Shifeng Pan, PhD
Executive Director, Discovery Chemistry
Novartis Institutes for Biomedical Research, GNF

Dr. Shifeng Pan currently serves as Executive Director of Discovery Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF), where he is responsible for discovery chemistry efforts at the Institute. He leads a team of approximately 70 chemists who are working to discover small molecule therapeutics and drug conjugates across multiple disease areas. In addition, he has responsibility for the Drug Metabolism and Pharmacokinetics (DMPK), Analytical Chemistry, and Compound Management groups at GNF. Since joining GNF in 1999 as one of the founding chemists, he has directly contributed to discover over ten clinical candidates including three approved drugs, Odomzo® (sonidegib) and BRAFTOVI® (encorafenib), and MAYZENT® (siponimod). In 2010, he received the prestigious VIVA award as a Novartis Leading Scientist. Dr. Pan received his Ph.D. in organic chemistry from New York University and B.S. in chemistry from Fudan University in Shanghai, China.

2022-05-25, [Free Online Symposium] The Science and Stories of Promising Biotech Startups – 1 (Jointly by PBSS and LSA)
2022-06-08, [Free Online Symposium] Highlights of 2021 FDA Approvals (a PBSS-CLS joint symposium)
2022-07-27, [Free Online Symposium] Success Stories and Lessons Learned from Recent FDA Approvals: VOXZOGO (vosoritide) by BioMarin Pharmaceutical Inc.
2022-08-17, [Free Online Symposium] Advances in Oncology
2022-09-15, [Free Online workshop] Immunogenicity of Biologic Drugs
2022-11-14, [Free Online Symposium] Advances in Cell therapy
©Pharmaceutical & BioScience Society, International; Last Modified: 5/16/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of phase 1 and 2 drug metabolites at mg-g scale with COAs. Also experts in natural products.
Veloxity Labs, LLC The unique employee-owned LC-MS/MS bioanalytical CRO with >100 years of experience and the responsiveness of a start-up! GLP and non-GLP.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad